Disease Domain | Count |
---|---|
Neoplasms | 13 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 10 |
TIL therapy | 2 |
Chemical drugs | 1 |
Target |
Mechanism SOCS1 stimulants |
Active Org. ![]() |
Originator Org. ![]() |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism USP1 inhibitors [+2] |
Active Org. |
Originator Org. ![]() |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. ![]() |
Originator Org. ![]() |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date31 Jan 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
KSQ-4279 ( USP1 ) | Solid tumor More | Phase 1 |
KSQ-001 ( SOCS1 ) | Non-Small Cell Lung Cancer More | IND Approval |
KSQ-427 ( USP2 ) | Neoplasms More | Preclinical |
KSQ-004 | Solid tumor More | Preclinical |
IO-1 (KSQ Therapeutics) | Neoplasms More | Discovery |